{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:38:57Z","timestamp":1793425137416,"version":"4.5.0"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Human papillomavirus (HPV) is the most common sexually transmitted infection. About 90% of HPV infections are transient, resolving without any need for intervention. Most of HPV infections are low-risk non-oncogenic. However, persistent infection with high-risk oncogenic HPV types is the cause of cervical as well as various other anogenital and oropharyngeal cancers. HPV infection on either cutaneous or mucosal surfaces activates both innate and adaptive antiviral immune cells including Langerhans and keratinocyte cells, natural killer cells, B and T cells. These cellular responses alongside their corresponding cytokine profiles have been associated with clearance of HPV infection and regression of HPV associated disease although the actual immune mechanisms involved are not well understood. Current HPV vaccines are based on self -assembled virus-like particles (VLP) from the major viral capsid protein and target the high-risk HPV types as well as two low-risk types responsible for genital warts. The vaccines generate antibody protection against new infections with no effect on already established infections and HPV-associated diseases. Certainly, despite the high effectiveness of current prophylactic HPV vaccines, therapeutic HPV vaccines are needed for treatment of already established HPV infections and disease. Although there have been great efforts in development of therapeutic vaccines, none is yet to be licensed due to low efficacy and safety concerns. There is therefore a need to understand both natural and vaccine-induced immunity, for development of effective and safe therapeutic HPV vaccines. Additionally, a better understanding of the immunogenicity of HPV vaccines, which are among the best subunit vaccines developed to date, may identify immune pathways that could be targeted for development of similarly effective vaccines for other diseases. This review summarises available literature on immune responses to both HPV infection and vaccination, with an aim of improving overall understanding on this subject. This may provide insights for better targeting of both therapeutic and prophylactic vaccines, not only for HPV but also other antigen targets.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1591297","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T04:10:20Z","timestamp":1750047020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Immune responses to human papillomavirus infection and vaccination"],"prefix":"10.3389","volume":"16","author":[{"given":"Eunice Wavinya","family":"Kiamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Goodier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662218","article-title":"Precision vaccine development: cues from natural immunity","volume":"12","author":"Barman","year":"2021","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121413","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/17455065211020702","article-title":"Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite","volume":"17","author":"Huber","year":"2021","journal-title":"Womens Health (Lond)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62342-2","article-title":"Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study","volume":"377","author":"Giuliano","year":"2011","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/v5112624","article-title":"Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response","volume":"5","author":"Amador-Molina","year":"2013","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2005.07.099","article-title":"Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study","volume":"99","author":"Sarkar","year":"2005","journal-title":"Gynecologic Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus immune evasion strategies target the infected cell and the local immune system","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/0304-419X(96)00020-0","article-title":"Papillomavirus infections\u2013a major cause of human cancers","volume":"1288","author":"zur Hausen","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"B9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.adaj.2019.10.010","article-title":"Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews","volume":"151","author":"Villa","year":"2020","journal-title":"J Am Dental Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.805695","article-title":"An update on human papilloma virus vaccines: history, types, protection, and efficacy","volume":"12","author":"Yousefi","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1186\/s12889-021-10907-5","article-title":"Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Public Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.16.1.1-17.2003","article-title":"Human papillomavirus and cervical cancer","volume":"16","author":"Burd","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies","volume":"5","author":"Graham","year":"2010","journal-title":"Future Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092188","article-title":"PI3K\/AKT\/mTOR signaling regulates the virus\/host cell crosstalk in HPV-positive cervical cancer cells","volume":"20","author":"Bossler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-020-00301-7","article-title":"\u03b2-Catenin: oncogenic role and therapeutic target in cervical cancer","volume":"53","author":"Wang","year":"2020","journal-title":"Biol Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1155\/2007\/613150","article-title":"Papillomavirus life cycle organization and biomarker selection","volume":"23","author":"Doorbar","year":"2007","journal-title":"Dis Markers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B23","article-title":"Immune responses to human papilloma viruses","volume":"130","author":"Stanley","year":"2009","journal-title":"Indian J Med Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002519","article-title":"Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections","volume":"8","author":"Surviladze","year":"2012","journal-title":"PloS Pathogens"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.24.13125-13135.2003","article-title":"Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses","volume":"77","author":"Shafti-Keramat","year":"2003","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.3.1565-1570.2001","article-title":"Human papillomavirus infection requires cell surface heparan sulfate","volume":"75","author":"Giroglou","year":"2001","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.3.1565-1570.2001","article-title":"The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes","volume":"274","author":"Joyce","year":"1999","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00998-07","article-title":"Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus","volume":"81","author":"Selinka","year":"2007","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)89549-0","article-title":"Estradiol beta-D-xyloside, an efficient primer for heparan sulfate biosynthesis","volume":"266","author":"Lugemwa","year":"1991","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"Richards","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908502106","article-title":"The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding","volume":"106","author":"Kines","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.04.004","article-title":"Current understanding of the mechanism of HPV infection","volume":"118","author":"Schiller","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02190-08","article-title":"Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus","volume":"83","author":"Johnson","year":"2009","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2019.04.009","article-title":"Extracellular events impacting human papillomavirus infections: Epithelial wounding to cell signaling involved in virus entry","volume":"7","author":"Ozbun","year":"2019","journal-title":"Papillomavirus Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.4838","article-title":"\u03b16 integrin is the main receptor of human papillomavirus type 16 VLP","volume":"283","author":"Yoon","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2001.1493","article-title":"Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions","volume":"299","author":"Selinka","year":"2002","journal-title":"Virology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0042-6822(02)00143-5","article-title":"Papillomaviruses infect cells via a clathrin-dependent pathway","volume":"307","author":"Day","year":"2003","journal-title":"Virology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-11","article-title":"Mechanisms of cell entry by human papillomaviruses: an overview","volume":"7","author":"Horvath","year":"2010","journal-title":"Virol J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.80.2.759-768.2006","article-title":"A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes","volume":"80","author":"K\u00e4mper","year":"2006","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000318","article-title":"Establishment of human papillomavirus infection requires cell cycle progression","volume":"5","author":"Pyeon","year":"2009","journal-title":"PloS Pathogens"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/v9090245","article-title":"Keratinocyte differentiation-dependent human papillomavirus gene regulation","volume":"9","author":"Graham","year":"2017","journal-title":"Viruses"},{"key":"B43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-12-394306-4.00012-5","article-title":"Asymmetric cell divisions in the epidermis","volume":"295","author":"Poulson","year":"2012","journal-title":"Int Rev Cell Mol Biol"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1038\/nature03922","article-title":"Asymmetric cell divisions promote stratification and differentiation of mammalian skin","volume":"437","author":"Lechler","year":"2005","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.22.11291-11300.2002","article-title":"Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription","volume":"76","author":"Ozbun","year":"2002","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.72.10.8166-8173.1998","article-title":"A fifteen-amino-acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro","volume":"72","author":"Kasukawa","year":"1998","journal-title":". J Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/path.2070","article-title":"Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer","volume":"210","author":"Hopman","year":"2006","journal-title":"J Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.50.7.600","article-title":"Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix","volume":"50","author":"Pirami","year":"1997","journal-title":"J Clin Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.65.2.606-612.1991","article-title":"Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm","volume":"65","author":"Cullen","year":"1991","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00546.x","article-title":"Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins","volume":"98","author":"Narisawa-Saito","year":"2007","journal-title":"Cancer Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2696","article-title":"Emerging roles of E2Fs in cancer: an exit from cell cycle control","volume":"9","author":"Chen","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.68.2.362-372.2004","article-title":"Pathogenesis of human papillomaviruses in differentiating epithelia","volume":"68","author":"Longworth","year":"2004","journal-title":"Microbiol Mol Biol Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7156\/v3i2p043","article-title":"Genomic instability induced by human papillomavirus oncogenes","volume":"3","author":"Chen","year":"2010","journal-title":"N Am J Med Sci (Boston)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015339","article-title":"Immunology and skin in health and disease","volume":"4","author":"Richmond","year":"2014","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.102137","article-title":"Interaction of syndecan and \u03b16\u03b24 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation","volume":"285","author":"Wang","year":"2010","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coviro.2016.01.001","article-title":"Type I interferons in viral control and immune regulation","volume":"16","author":"Teijaro","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00682","article-title":"Potential mechanisms for HPV vaccine-induced long-term protection","volume":"118","author":"Stanley","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.2.209-220.2001","article-title":"Cell-mediated immune response to human papillomavirus infection","volume":"8","author":"Scott","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2011.07.020","article-title":"Mycobacterium bovis BCG and purified protein derivative-induced reduction in the CD80 expression and the antigen up-take function of dendritic cells from patients with cervical cancer","volume":"159","author":"Manickam","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004314","article-title":"Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1","volume":"10","author":"Handisurya","year":"2014","journal-title":"PloS Pathog"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12462790","article-title":"Immunoelectron microscopical localization of human papillomavirus type 16 L1 and E4 proteins in cervical keratinocytes cultured in vivo","volume":"100","author":"Sterling","year":"1993","journal-title":"J Invest Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636915","article-title":"Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells","volume":"37","author":"Black","year":"2007","journal-title":"Eur J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.8.13.7926369","article-title":"Cytokine production by epithelial cells","volume":"8","author":"Stadnyk","year":"1994","journal-title":"FASEB J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.66.1.33","article-title":"Role of cytokines in epidermal Langerhans cell migration","volume":"66","author":"Wang","year":"1999","journal-title":"J Leukoc Biol"},{"key":"B65","article-title":"Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines","volume":"142","author":"Woodworth","year":"1993","journal-title":"Am J Pathol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pvr.2017.08.002","article-title":"Modulation of antigen presenting cell functions during chronic HPV infection","volume":"4","author":"Bashaw","year":"2017","journal-title":"Papillomavirus Res"},{"key":"B67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2013.11.024","article-title":"Toll-like receptors in antiviral innate immunity","volume":"426","author":"Lester","year":"2014","journal-title":"J Mol Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700530","article-title":"Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9","volume":"127","author":"Lebre","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700559","article-title":"Human keratinocyte Toll-like receptors promote distinct immune responses","volume":"127","author":"Miller","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.09.016","article-title":"Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha\/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses","volume":"23","author":"Yang","year":"2005","journal-title":"Immunity"},{"key":"B71","article-title":"TLR9 expression, langerhans cell density and lymphocytic infiltration in progressing cervical intraepithelial neoplasia","volume":"296","author":"Manjgaladze","year":"2019","journal-title":"Georgian Med News"},{"key":"B72","article-title":"Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells","volume":"52","author":"Woodworth","year":"1992","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.10.4767-4775.1990","article-title":"Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells","volume":"64","author":"Woodworth","year":"1990","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.10.6764","article-title":"Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis","volume":"275","author":"Park","year":"2000","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"crossref","DOI":"10.1101\/gad.12.13.2061","article-title":"Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity","volume":"12","author":"Ronco","year":"1998","journal-title":"Genes Dev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.14.5867","article-title":"TLR9 expression in uterine cervical lesions of Uyghur women correlate with cervical cancer progression and selective silencing of human papillomavirus 16 E6 and E7 oncoproteins in vitro","volume":"15","author":"Hao","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1159\/000292394","article-title":"HPV DNA positivity and natural killer cell activity in the clinical outcome of mild cervical dysplasia: integration between virus and immune system","volume":"39","author":"Garzetti","year":"1995","journal-title":"Gynecol Obstet Invest"},{"key":"B78","article-title":"HPV and intraepithelial neoplasia recurrent lesions of the lower genital tract: assessment of the immune system","volume":"19","author":"Stentella","year":"1998","journal-title":"Eur J Gynaecol Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(90)90114-Z","article-title":"Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix","volume":"36","author":"Vaquer","year":"1990","journal-title":"Gynecol Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-186","article-title":"Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions","volume":"9","author":"Garcia-Iglesias","year":"2009","journal-title":"BMC Cancer"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2013.12.005","article-title":"Altered phenotype and function of NK cells infiltrating Human Papillomavirus (HPV)-associated genital warts during HIV infection","volume":"150","author":"Bere","year":"2014","journal-title":"Clin Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12915-017-0392-4","article-title":"Tissue macrophages: heterogeneity and functions","volume":"15","author":"Gordon","year":"2017","journal-title":"BMC Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1987.tb02296.x","article-title":"Tissue macrophage response in human papillomavirus infection and cervical intraepithelial neoplasia","volume":"94","author":"Tay","year":"1987","journal-title":"Br J Obstet Gynaecol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28410","article-title":"Single-cell transcriptomic analysis of the role of HPV16-positive macrophages in cervical cancer prognosis","volume":"95","author":"Wang","year":"2023","journal-title":"J Med Virology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"crossref","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12257","article-title":"Tumor-associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells","volume":"122","author":"Ding","year":"2014","journal-title":"Apmis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.30","article-title":"Microparticles mediate human papillomavirus type 6 or 11 infection of human macrophages","volume":"14","author":"Cao","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B89","article-title":"Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization","volume":"84","author":"Cumberbatch","year":"1995","journal-title":"Immunology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.5.2390","article-title":"Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance","volume":"151","author":"Enk","year":"1993","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1365-2249.1999.00826.x","article-title":"The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium","volume":"116","author":"Mota","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/BF02505819","article-title":"The role of dendritic cells in cutaneous immunity","volume":"288","author":"Lappin","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"99s","DOI":"10.1111\/1523-1747.ep12316241","article-title":"Skin-associated lymphoid tissue in human immunodeficiency virus-1, human papillomavirus, and herpes simplex virus infections","volume":"105","author":"Memar","year":"1995","journal-title":"J Invest Dermatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.15.8378-8385.2003","article-title":"Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin","volume":"77","author":"Matthews","year":"2003","journal-title":"J Virol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1987.tb02244.x","article-title":"Subpopulations of Langerhans\u2019 cells in cervical neoplasia","volume":"94","author":"Tay","year":"1987","journal-title":"Br J Obstet Gynaecol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/102.6.768","article-title":"Immunological events in regressing genital warts","volume":"102","author":"Coleman","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"B97","article-title":"Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment","volume":"11","author":"Christine","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200389","article-title":"Profiling HPV-16\u2013specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients","volume":"217","author":"Bhatt","year":"2020","journal-title":"J Exp Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82678-0","article-title":"Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2","volume":"88","author":"Dillon","year":"2007","journal-title":"J Gen Virol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1086\/513992","article-title":"Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia","volume":"175","author":"Nakagawa","year":"1997","journal-title":"J Infect Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.10.7176","article-title":"IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions","volume":"179","author":"Seresini","year":"2007","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2567.2010.03277.x","article-title":"CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix","volume":"131","author":"Seresini","year":"2010","journal-title":"Immunology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29913","article-title":"Immunodeficiency and the risk of cervical intraepithelial neoplasia 2\/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study","volume":"138","author":"Clifford","year":"2016","journal-title":"Int J Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji073","article-title":"Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women","volume":"97","author":"Strickler","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Global Health"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000455","article-title":"Long-term cumulative detection of human papillomavirus among HIV seropositive women","volume":"28","author":"Massad","year":"2014","journal-title":"AIDS"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800147-9.00005-4","article-title":"How to trigger a killer: modulation of natural killer cell reactivity on many levels","volume":"124","author":"Watzl","year":"2014","journal-title":"Adv Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.148.8.2617","article-title":"Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16","volume":"148","author":"Chen","year":"1992","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.1.110","article-title":"Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen","volume":"88","author":"Chen","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.560","article-title":"Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions","volume":"76","author":"Bontkes","year":"1997","journal-title":"Br J Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2008.01936.x","article-title":"Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis","volume":"115","author":"Woo","year":"2008","journal-title":"Bjog"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050265","article-title":"HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions","volume":"42","author":"Evans","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"B114","article-title":"Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes","volume":"57","author":"Evans","year":"1997","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.6.4.494-498.1999","article-title":"CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses","volume":"6","author":"Nakagawa","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1086\/315706","article-title":"Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens","volume":"182","author":"Nakagawa","year":"2000","journal-title":"J Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910460614","article-title":"Loss of MHC class-I expression in cervical carcinomas","volume":"46","author":"Connor","year":"1990","journal-title":"Int J Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0171-2985(11)80222-6","article-title":"Expression of immune associated surface antigens of keratinocytes in human papillomavirus-derived lesions","volume":"188","author":"Viac","year":"1993","journal-title":"Immunobiology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1399-0039.1993.tb01981.x","article-title":"HLA class I expression and HPV-16 sequences in premalignant and Malignant lesions of the cervix","volume":"41","author":"Torres","year":"1993","journal-title":"Tissue Antigens"},{"key":"B120","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1128\/cdli.7.1.79-85.2000","article-title":"Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease","volume":"7","author":"Vambutas","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2008.00484.x","article-title":"Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients","volume":"54","author":"Lopez","year":"2008","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.07.100","article-title":"Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study","volume":"99","author":"Bierl","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01065-16","article-title":"Human papillomavirus entry: hiding in a bubble","volume":"90","author":"DiGiuseppe","year":"2016","journal-title":"J Virol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: An update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int J Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00152","article-title":"Productive lifecycle of human papillomaviruses that depends upon squamous epithelial differentiation","volume":"3","author":"Kajitani","year":"2012","journal-title":"Front Microbiol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34408","article-title":"Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus","volume":"10","author":"Herrin","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1016\/j.vaccine.2020.07.017","article-title":"Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines","volume":"38","author":"Tsang","year":"2020","journal-title":"Vaccine"},{"key":"B128","doi-asserted-by":"crossref","DOI":"10.1016\/S0042-6822(03)00196-X","article-title":"Characterization of IgA response among women with incident HPV 16 infection","volume":"312","author":"Onda","year":"2003","journal-title":"Virology"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<529::AID-IJC7>3.0.CO;2-V","article-title":"Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions","volume":"75","author":"Sasagawa","year":"1998","journal-title":"Int J Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.3.4.403-410.1996","article-title":"Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions","volume":"3","author":"Sasagawa","year":"1996","journal-title":"Clin Diagn Lab Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural acquired immunity against subsequent genital human papillomavirus infection: A systematic review and meta-analysis","volume":"213","author":"Beachler","year":"2016","journal-title":"J Infect Dis"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.06.007","article-title":"Seroconversion following anal and genital HPV infection in men: the HIM study","volume":"1","author":"Giuliano","year":"2015","journal-title":"Papillomavirus Res (Amsterdam Netherlands)"},{"key":"B134","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/infdis\/jiy112","article-title":"Risk of HPV-16\/18 infections and associated cervical abnormalities in women seropositive for naturally acquired antibodies: pooled analysis based on control arms of two large clinical trials","volume":"218","author":"Safaeian","year":"2018","journal-title":"J Infect Dis"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100185","article-title":"Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature","volume":"8","author":"Pattyn","year":"2019","journal-title":"Papillomavirus Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1086\/315364","article-title":"Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions","volume":"181","author":"Hagensee","year":"2000","journal-title":"J Infect Dis"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-2-409","article-title":"Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16","volume":"80","author":"Bontkes","year":"1999","journal-title":"J Gen Virol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000355964","article-title":"Host responses to infection with human papillomavirus","volume":"45","author":"Stanley","year":"2014","journal-title":"Curr Probl Dermatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-5-19","article-title":"HPV - immune response to infection and vaccination","volume":"5","author":"Stanley","year":"2010","journal-title":"Infect Agents Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20901","article-title":"Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia","volume":"79","author":"Passmore","year":"2007","journal-title":"J Med Virol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83458-0","article-title":"Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease","volume":"89","author":"Mbulawa","year":"2008","journal-title":"J Gen Virol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccines"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","author":"Scherpenisse","year":"2013","journal-title":"PloS One"},{"key":"B145","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"B146","unstructured":"HPV_vaccine_information_sheet_1217\n          \n          \n          \n          2017"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.119","article-title":"Chapter 11: HPV vaccines: commercial research & development","author":"Inglis","year":"2006","journal-title":"Vaccine"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00275-X","article-title":"Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial","volume":"23","author":"Zhu","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B149","unstructured":"WHO updates recommendations on HPV vaccination schedule\n          \n          \n          \n          2022"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.11.076","article-title":"Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence","volume":"39","author":"Brown","year":"2021","journal-title":"Vaccine"},{"key":"B152","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","volume":"6","author":"De Vincenzo","year":"2014","journal-title":"Int J Womens Health"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"B155","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines","volume":"17","author":"Arbyn","year":"2018","journal-title":"A Cochrane Rev randomized trials. Expert Rev Vaccines"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3493.","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-018-1098-3","article-title":"Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review","volume":"16","author":"Harder","year":"2018","journal-title":"BMC Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111912","article-title":"Prophylactic human papillomavirus vaccination: from the origin to the current state","volume":"10","author":"Akhatova","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1103936","article-title":"HPV vaccines: Translating immunogenicity into efficacy","volume":"12","author":"Turner","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2008.06.029","article-title":"Impact of vaccination with Cervarix\u2122 on subsequent HPV-16\/18 infection and cervical disease in women 15\u201325 years of age","volume":"110","author":"Harper","year":"2008","journal-title":"Gynecologic Oncol"},{"key":"B166","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4\u00b75 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"key":"B168","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgae032","article-title":"HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial","volume":"2024","author":"Porras","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose human papillomavirus vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evidence"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9&x2013;14 years in Tanzania (DoRIS) with one dose in young women aged 15&x2013;20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials","volume":"12","author":"Baisley","year":"2024","journal-title":"Lancet Global Health"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00477-7","article-title":"Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial","volume":"13","author":"Watson-Jones","year":"2025","journal-title":"Lancet Global Health"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix797","article-title":"A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries","volume":"66","author":"Kjaer","year":"2017","journal-title":"Clin Infect Diseases"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00287","article-title":"Eliminating Deaths From Cervical Cancer-Report of a Panel at the 7th Annual Symposium on Global Cancer Research, a Satellite Meeting at the Consortium of Universities for Global Health 10th Annual Meeting","volume":"5","author":"Binagwaho","year":"2019","journal-title":"J Glob Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"Bmj"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-1902","article-title":"Human papillomavirus vaccine effectiveness and herd protection in young women","volume":"143","author":"Spinner","year":"2019","journal-title":"Pediatrics"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.02.019","article-title":"Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine","volume":"23","author":"Nardelli-Haefliger","year":"2005","journal-title":"Vaccine"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033736","article-title":"Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers","volume":"7","author":"Huo","year":"2012","journal-title":"PloS One"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.01.013","article-title":"Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants","volume":"28","author":"Cho","year":"2010","journal-title":"Vaccine"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2872","article-title":"Understanding and learning from the success of prophylactic human papillomavirus vaccines","volume":"10","author":"Schiller","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22693","article-title":"Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination","volume":"9","author":"Scherpenisse","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000429","article-title":"Characterization of immunoglobulin A\/G responses during 3 doses of the human papillomavirus-16\/18 ASO4-adjuvanted vaccine","volume":"43","author":"Gon\u00e7alves","year":"2016","journal-title":"Sex Transm Dis"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25887","article-title":"Long-term persistence of systemic and mucosal immune response to HPV-16\/18 AS04-adjuvanted vaccine in preteen\/adolescent girls and young women","volume":"129","author":"Pet\u00e4j\u00e4","year":"2011","journal-title":"Int J Cancer"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.9.3957-3961.1994","article-title":"Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination","volume":"62","author":"Bouvet","year":"1994","journal-title":"Infect Immun"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis619","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women","volume":"207","author":"Sow","year":"2013","journal-title":"J Infect diseases"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1008877","article-title":"Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa","volume":"11","author":"Mugo","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000731","article-title":"Non-vaccine-type human papillomavirus prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection","volume":"45","author":"Saccucci","year":"2018","journal-title":"Sex Transm Dis"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2020.100203","article-title":"Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up","volume":"10","author":"Olsson","year":"2020","journal-title":"Papillomavirus Res"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1058458","article-title":"Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes","volume":"12","author":"Hern\u00e1ndez-\u00c1vila","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1050570","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial","volume":"11","author":"Leung","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J Infect Dis"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100401","article-title":"Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries","volume":"23","author":"Kjaer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-3947","article-title":"4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years","volume":"140","author":"Ferris","year":"2017","journal-title":"Pediatrics"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.074","article-title":"Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women","volume":"26","author":"Kemp","year":"2008","journal-title":"Vaccine"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine","volume":"6","author":"Schwarz","year":"2010","journal-title":"Hum Vaccin"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.146","article-title":"HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood","volume":"23","author":"Pinto","year":"2005","journal-title":"Vaccine"},{"key":"B204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-1-4160-3611-1.50006-4","article-title":"Chapter 2 - Vaccine immunology","volume-title":"Vaccines","author":"Siegrist","year":"2008"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004461","article-title":"Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity","volume":"10","author":"Scherer","year":"2014","journal-title":"PloS Pathog"},{"key":"B206","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ebiom.2016.06.042","article-title":"A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects","volume":"10","author":"Scherer","year":"2016","journal-title":"EBioMedicine"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix566","article-title":"Analysis of memory B-cell responses reveals suboptimal dosing schedule of a licensed vaccine","volume":"217","author":"Scherer","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"B208","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/vaccines8010026","article-title":"HPV-specific systemic antibody responses and memory B cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy","volume":"8","author":"Nicoli","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137195","article-title":"Circulating CXCR5(+)CD4(+) T follicular-like helper cell and memory B cell responses to human papillomavirus vaccines","volume":"10","author":"Matsui","year":"2015","journal-title":"PloS One"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.92.5.673","article-title":"An autoradiographic study of plasma cell and lymphocyte survival in rat popliteal lymph nodes","volume":"92","author":"Miller","year":"1964","journal-title":". J Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6616(02)00039-6","article-title":"Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells","volume":"106","author":"Lenz","year":"2003","journal-title":"Clin Immunol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J Control Release"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103312","article-title":"Innate immunity mediates follicular transport of particulate but not soluble protein antigen","volume":"188","author":"Link","year":"2012","journal-title":"J Immunol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(89)80024-1","article-title":"Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases","volume":"32","author":"Lee","year":"1989","journal-title":"Gynecol Oncol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.4543","article-title":"Long-lasting increased risk of human papillomavirus-related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: A population-based cohort study","volume":"35","author":"Ebisch","year":"2017","journal-title":"J Clin Oncol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010045","article-title":"Efficacy of HPV vaccination in women receiving LEEP for cervical dysplasia: A single institution\u2019s experience","volume":"8","author":"Petrillo","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2016.1176533","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies","volume":"15","author":"Vici","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1086\/498164","article-title":"Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination","volume":"192","author":"Vandepapeliere","year":"2005","journal-title":"J Infect Dis"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00766","article-title":"Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results","volume":"10","author":"Mastelic-Gavillet","year":"2019","journal-title":"Front Immunol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-065X.2010.00916.x","article-title":"Programmed cell death of dendritic cells in immune regulation","volume":"236","author":"Chen","year":"2010","journal-title":"Immunol Rev"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<725::AID-IJC19>3.0.CO;2-K","article-title":"Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine","volume":"86","author":"Chang","year":"2000","journal-title":"Int J Cancer"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines2020422","article-title":"Therapeutic vaccine strategies against human papillomavirus","volume":"2","author":"Khallouf","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"B228","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.vaccine.2020.11.066","article-title":"Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists","volume":"39","author":"Zacharia","year":"2021","journal-title":"Vaccine"},{"key":"B229","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-019-5725-y","article-title":"Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication","volume":"19","author":"Maynard","year":"2019","journal-title":"BMC Cancer"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1362770","article-title":"Current status and future directions for the development of human papillomavirus vaccines","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12985-024-02397-9","article-title":"The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV)","volume":"21","author":"Movahed","year":"2024","journal-title":"Virol J"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6998","article-title":"Novel combination immunotherapy and clinical activity in patients with HPV-associated cancers: A nonrandomized clinical trial","volume":"11","author":"Floudas","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1591297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T04:10:24Z","timestamp":1750047024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1591297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":232,"alternative-id":["10.3389\/fimmu.2025.1591297"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1591297","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"article-number":"1591297"}}